tiprankstipranks
Advertisement
Advertisement
Nurix Therapeutics price target raised to $35 from $32 at Piper Sandler
PremiumThe FlyNurix Therapeutics price target raised to $35 from $32 at Piper Sandler
2M ago
Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright
Premium
The Fly
Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright
2M ago
Nurix Therapeutics, Inc. Reported Earnings. Did it Beat Estimates?
Premium
Earning Releases
Nurix Therapeutics, Inc. Reported Earnings. Did it Beat Estimates?
2M ago
Nurix Therapeutics Advances Study for NX-5948 in CLL and SLL Patients
PremiumCompany AnnouncementsNurix Therapeutics Advances Study for NX-5948 in CLL and SLL Patients
3M ago
HOOD, IBTA, IRDM: Cathie Wood Buys the Dip in Robinhood, Sells Ibotta and Iridium Stocks
Premium
Market News
HOOD, IBTA, IRDM: Cathie Wood Buys the Dip in Robinhood, Sells Ibotta and Iridium Stocks
4M ago
Cathie Wood Capitalizes the Surge in Iridium and Biotech Stocks
Premium
Market News
Cathie Wood Capitalizes the Surge in Iridium and Biotech Stocks
4M ago
Nurix Therapeutics Reports Promising Data at Hematology Meeting
PremiumCompany AnnouncementsNurix Therapeutics Reports Promising Data at Hematology Meeting
4M ago
Nurix Therapeutics presents data from Phase 1 trial of bexobrutideg
Premium
The Fly
Nurix Therapeutics presents data from Phase 1 trial of bexobrutideg
4M ago
Nurix presents new clinical data from Phase 1a/1b NX-5948-301 study
Premium
The Fly
Nurix presents new clinical data from Phase 1a/1b NX-5948-301 study
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100